Recent studies have shown that local production of SPARC is essential for maintenance of the integrity of cardiac ECM after MI, emphasizing the potential therapeutic application of this protein to prevent cardiac dilatation and dysfunction after MI [35]. This evidence concerns the gene SPARC and myocardial infarction.